Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs. This story matters for General News readers tracking baha. Reported by nytimes.com. Read the full original at the source link below.
Originally reported by nytimes.com. BahaNews curates and briefs the general news stories that matter. Our editorial policy →